Jonathan W. Said mainly focuses on Pathology, Cancer research, Lymphoma, Internal medicine and Immunology. His work in Pathology is not limited to one particular discipline; it also encompasses Cancer. His Cancer research research is multidisciplinary, relying on both Gene expression, Cancer cell, Apoptosis, Breast cancer and Prostate cancer.
His Lymphoma study integrates concerns from other disciplines, such as T cell, AIDS-related lymphoma and B cell. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Oncology. Jonathan W. Said has researched Primary effusion lymphoma in several fields, including Kaposi's sarcoma-associated herpesvirus and Growth factor.
Jonathan W. Said spends much of his time researching Pathology, Cancer research, Internal medicine, Lymphoma and Immunology. The study incorporates disciplines such as T cell, Immunophenotyping and Immunoperoxidase in addition to Pathology. His study focuses on the intersection of Cancer research and fields such as In vivo with connections in the field of Pharmacology.
His Internal medicine study incorporates themes from Endocrinology and Oncology. His research integrates issues of Virus, Virology and B cell in his study of Lymphoma. His work carried out in the field of Renal cell carcinoma brings together such families of science as Carcinoma, Surgery, Nephrectomy and Kidney disease.
Jonathan W. Said focuses on Cancer research, Internal medicine, Immunology, Pathology and Oncology. His Cancer research research is multidisciplinary, incorporating perspectives in Cyclin D1, Gene silencing, Oncogene and Cell growth. His research on Internal medicine frequently links to adjacent areas such as Endocrinology.
His Immunology study frequently involves adjacent topics like Cancer. The various areas that Jonathan W. Said examines in his Pathology study include Large cell and PTEN. His Lymphoma research is multidisciplinary, incorporating perspectives in T cell and Gene rearrangement.
Cancer research, Immunology, Pathology, Lymphoma and Immune system are his primary areas of study. His Cancer research research is multidisciplinary, relying on both T cell, Transcription factor, Regulation of gene expression, Gene silencing and Bromodomain. As part of his studies on Pathology, Jonathan W. Said frequently links adjacent subjects like PTEN.
His study looks at the intersection of PTEN and topics like Cancer with Clear cell renal cell carcinoma. His Lymphoma research includes elements of Gene rearrangement and Germline mutation. His Immune system research incorporates themes from Acquired immunodeficiency syndrome, Viral load, Lymph node and Autopsy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Kaposi's Sarcoma–Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity–Based Lymphomas
Ethel Cesarman;Yuan Chang;Patrick S. Moore;Jonathan W. Said.
The New England Journal of Medicine (1995)
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.
E Elstner;C Müller;K Koshizuka;E A Williamson.
Proceedings of the National Academy of Sciences of the United States of America (1998)
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Amnon Zisman;Allan J. Pantuck;Fredrick Dorey;Jonathan W. Said.
Journal of Clinical Oncology (2001)
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
Young E. Whang;Xinyi Wu;Hiroyoshi Suzuki;Robert E. Reiter.
Proceedings of the National Academy of Sciences of the United States of America (1998)
Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma
Amnon Zisman;Allan J. Pantuck;Jeffery Wieder;Debby H. Chao.
Journal of Clinical Oncology (2002)
Ligand for Peroxisome Proliferator-activated Receptor γ (Troglitazone) Has Potent Antitumor Effect against Human Prostate Cancer Both in Vitro and in Vivo
T Kubota;K Koshizuka;E A Williamson;H Asou.
Cancer Research (1998)
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.
Gu Z;Thomas G;Yamashiro J;Shintaku Ip.
Oncogene (2000)
Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky;Reiko E. Yamada;Jonathan Said;Geraldine S. Pinkus.
Clinical Cancer Research (2011)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Edgardo R. Parrilla Castellar;Elaine S. Jaffe;Jonathan W. Said;Steven H. Swerdlow.
Blood (2014)
Evidence for Clonal Outgrowth of Androgen-independent Prostate Cancer Cells from Androgen-dependent Tumors through a Two-Step Process
Noah Craft;Chloe Chhor;Chris Tran;Arie Belldegrun.
Cancer Research (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Cedars-Sinai Medical Center
University of California, Los Angeles
University of California, Los Angeles
University of California, Los Angeles
Brigham and Women's Hospital
Cleveland Clinic
University of California, Los Angeles
University of Southern California
University of California, Los Angeles
University of California, Los Angeles
Linnaeus University
University of Chicago
Luminous Computing
Auburn University
Freie Universität Berlin
Shanghai Jiao Tong University
General Electric (United States)
University of Tennessee at Knoxville
Grenoble Alpes University
Boston University
Forschungszentrum Jülich
University of Minnesota
University of Turin
Princeton University
Chinese University of Hong Kong